Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Beyond Awareness: Hope for a CMV Vaccine! An Introduction to the Conference, "CMV Vaccine Development-How Close Are We?" (27-28 September 2023).
Vaccines (Basel)
October 2024
Program Officer at Virology Branch, Division of Microbiology and Infectious Diseases, NIAID, NIH, 5601 Fisher's Lane, Rockville, MD 20892, USA.
Congenital cytomegalovirus (cCMV) is the most common infectious cause of disability in children. The major theme of this National Institute of Allergy and Infectious Diseases (NIAID) workshop, "CMV Vaccine Development-How Close Are We?", was to report progress on the development of a pre-conception vaccine that could confer protective immunity for women of child-bearing age. Such a vaccine could result in a reduced cCMV disease burden, although other populations, including solid organ transplant and hematopoietic stem cell transplant patients, could benefit as well.
View Article and Find Full Text PDFNeoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study.
Cancers (Basel)
October 2024
Department of Medical Oncology, Faculty of Medicine, İstanbul Medipol University, Istanbul 34214, Türkiye.
Following the results of the phase 3 KEYNOTE-522 trial, the U.S. Food and Drug Administration approved pembrolizumab, a humanized IgG4 kappa monoclonal antibody, in combination with neoadjuvant chemotherapy as a new standard of care for high-risk early-stage triple-negative breast cancer (TNBC).
View Article and Find Full Text PDFCalibrating Observational Health Record Data Against a Randomized Trial.
JAMA Netw Open
September 2024
Aetion, New York, New York.
Importance: The conditions required for health record data sources to accurately assess treatment effectiveness remain unclear. Emulation of randomized clinical trials (RCTs) with health record data and subsequent calibration of the results can help elucidate this.
Objective: To pilot an emulation of the KEYNOTE-189 RCT using a commercially available electronic health record (EHR) data source.
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
September 2024
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Article Synopsis
- The KEYNOTE-671 trial showed that adding pembrolizumab to neoadjuvant chemotherapy significantly enhanced event-free survival in patients with early-stage non-small-cell lung cancer (NSCLC).
- The trial involved randomizing nearly 800 participants across 189 medical centers, comparing treatment with pembrolizumab plus chemotherapy against a placebo plus chemotherapy.
- Results indicated that after 36 months, overall survival was higher in the pembrolizumab group (71%) compared to the placebo group (64%), suggesting a positive impact of the immunotherapy.
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.
BMC Cancer
July 2024
Department of Medical Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil. Universidad de Las Palmas de Gran Canaria, Gran Canaria, Spain.
Article Synopsis
- The trial assessed the effectiveness of adding epacadostat, an IDO1 inhibitor, to pembrolizumab and chemotherapy for treating advanced non-small cell lung cancer (NSCLC) without targetable mutations.
- Patients were divided into three treatment groups: one receiving the combination of epacadostat, pembrolizumab, and chemotherapy; another receiving epacadostat and pembrolizumab; and a placebo group also receiving pembrolizumab and chemotherapy.
- Results showed that the combination of epacadostat, pembrolizumab, and chemotherapy had a lower objective response rate (26.4%) compared to the placebo combination (44.8%), indicating that adding epacadostat might not improve treatment outcomes for patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!